NASDAQ: REPL: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Class Action Lawsuit Against Replimune Group, Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Replimune Group, Inc. (“Replimune”) (
NASDAQ: REPL) on behalf of those who purchased or otherwise acquired Replimune securities between November 22, 2024, and July 21, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is September 22, 2025.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPLNEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”)(
NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit - REPLSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit - REPLNEW YORK - August 13, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. (
NASDAQ: REPL) of a class action securities lawsuit.
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ReplimuneFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Replimune To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Reminds Investors of Class Actions Against Neogen, Alto, RxSight, and Replimune and Encourages Investors to Contact the FirmNEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Neogen Corporation (
NASDAQ:NEOG), Alto Neuroscience, Inc. (
NYSE:ANRO), RxSight, Inc. (
NASDAQ:RXST), and Replimune Group, Inc. (
NASDAQ:REPL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Replimune Group, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights - REPLSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. (NASDAQ: REPL)NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Replimune Group, Inc. (“Replimune” or the “Company”) (
NASDAQ: REPL) between November 22, 2024 and July 21, 2025, inclusive, alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its senior officers (the “Complaint”).
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPLNEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”)(
NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REPLSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Replimune Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REPLNEW YORK - August 7, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. (
NASDAQ: REPL) of a class action securities lawsuit.
Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate UpdateWOBURN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2025 and provided a business update.
Shareholders That Lost Money on Replimune Group, Inc. (REPL) Should Contact Levi & Korsinsky About Pending Class Action - REPLSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Shareholders That Lost Money on Replimune Group, Inc. (REPL) Should Contact Levi & Korsinsky About Pending Class Action - REPLNEW YORK - August 6, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. (
NASDAQ: REPL) of a class action securities lawsuit.
Bragar Eagel & Squire, P.C. Reminds Investors of Class Actions Against Neogen, Alto, RxSight, and Replimune and Encourages Investors to Contact the FirmNEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Neogen Corporation (
NASDAQ:NEOG), Alto Neuroscience, Inc. (
NYSE:ANRO), RxSight, Inc. (
NASDAQ:RXST), and Replimune Group, Inc. (
NASDAQ:REPL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
